Atea Pharmaceuticals (AVIR) Earnings Date, Estimates & Call Transcripts $3.35 0.00 (0.00%) (As of 11:10 AM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Atea Pharmaceuticals Latest Earnings SummaryUpcoming Q3 Earnings DateNov. 7After Market ClosesConfirmedActual EPS (Aug. 7) -$0.48 Beat By $0.28 Consensus EPS (Aug. 7) -$0.76 Atea Pharmaceuticals posted Q2 2024 earnings on August 7, 2024, reporting an EPS of -$0.48, which topped the consensus estimate of -$0.76 by $0.28. With a trailing EPS of -$2.10, Atea Pharmaceuticals' earnings are expected to grow next year, from ($2.21) to ($1.79) per share. Conference Call AudioEarnings Press ReleaseEarnings Slide DeckAVIR Upcoming EarningsAtea Pharmaceuticals' next earnings date is scheduled for Thursday, November 7, 2024, with a conference call scheduled for at 4:30 PM ET. Interested parties can register for or listen to the call. Get Atea Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atea Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAVIR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AVIR Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Huge AlertsNASDAQ traded stock with a BIG short position. Small cap NASDAQ firm is an innovative leader in non-opioid pain therapeutics. The company’s offerings could significantly aid in stopping the opioid crisis and create maximum shareholder growth!See how this NASDAQ Bio-tech is offering viable solutions Atea Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.63-$0.57-$0.60Q2 20242-$0.79-$0.75-$0.77Q3 20242-$0.85-$0.43-$0.64Q4 20242-$0.92-$0.45-$0.69FY 20248-$3.19-$2.20-$2.70Q1 20251-$0.48-$0.48-$0.48Q2 20251-$0.48-$0.48-$0.48Q3 20251-$0.49-$0.49-$0.49Q4 20251-$0.48-$0.48-$0.48FY 20254($1.93)($1.93)($1.93) Atea Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/7/2024(Confirmed)------- 8/7/2024Q2 2024-$0.76-$0.48+$0.28-$0.48-- 5/14/2024Q1 2024-$0.61-$0.75 -$0.14-$0.75-- 2/28/2024Q4 2023-$0.44-$0.47 -$0.03-$0.47-- 11/8/2023Q3 2023-$0.46-$0.40+$0.06-$0.40-- 8/8/2023Q2 2023-$0.47-$0.34+$0.13-$0.34-- 5/8/2023Q1 2023-$0.51-$0.43+$0.08-$0.43-- Get the Latest News and Ratings for AVIR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/2023Q4 2022-$0.45-$0.41+$0.04-$0.41-- 11/7/2022Q3 2022-$0.44-$0.10+$0.34-$0.10-- Atea Pharmaceuticals Earnings - Frequently Asked Questions When is Atea Pharmaceuticals's earnings date? Atea Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Thursday, November 7th, 2024. Learn more on AVIR's earnings history. Did Atea Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Atea Pharmaceuticals (NASDAQ:AVIR) reported ($0.48) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.76) by $0.28. Learn more on analysts' earnings estimate vs. AVIR's actual earnings. How can I listen to Atea Pharmaceuticals's earnings conference call? The conference call for Atea Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How much revenue does Atea Pharmaceuticals generate each year? Atea Pharmaceuticals (NASDAQ:AVIR) has a recorded annual revenue of $351.37 million. How much profit does Atea Pharmaceuticals generate each year? Atea Pharmaceuticals (NASDAQ:AVIR) has a recorded net income of -$135.96 million. AVIR has generated -$2.10 earnings per share over the last four quarters. What is Atea Pharmaceuticals's EPS forecast for next year? Atea Pharmaceuticals's earnings are expected to grow from ($2.21) per share to ($1.79) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Inovio Pharmaceuticals Earnings Date Disc Medicine Earnings Date Immatics Earnings Date Bicycle Therapeutics Earnings Date ArriVent BioPharma Earnings Date Evolus Earnings Date CARGO Therapeutics Earnings Date Phathom Pharmaceuticals Earnings Date IGM Biosciences Earnings Date Arcutis Biotherapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run NASDAQ traded stock with a BIG short position. (Ad)Small cap NASDAQ firm is an innovative leader in non-opioid pain therapeutics. The company’s offerings could significantly aid in stopping the opioid crisis and create maximum shareholder growth!See how this NASDAQ Bio-tech is offering viable solutions This page (NASDAQ:AVIR) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
